The genes for Nipah virus (NiV) proteins were amplified from viral RNA, cloned into the plasmid pTriEx-3 Hygro, expressed, and purified using immobilized metal affinity chromatography. The recombinant N, F, and G NiV proteins (rNiV-N, rNiV-F, and rNiV-G), were successfully expressed in Escherichia coli and purified with a yield of 4, 16, and 4 mg/L, respectively. All 3 recombinant viral proteins reacted with all 19 samples of NiV-positive human sera. The rNiV-N and rNiV-G proteins were the most immunogenic. The recombinant viral proteins did not react with any of the 12 NiV-negative sera. However, serum from a patient with a late-onset relapsing NiV infection complication was found to be primarily reactive to rNiV-G only. Additionally, there is a distinctive variation in the profile of antigen-reactive bands between the sample from a case of relapsing NiV encephalitis and that of acute NiV infection. The overall findings of this study suggest that the recombinant viral proteins have the potential to be developed further for use in the detection of NiV infection, and continuous biosurveillance of NiV infection in resource-limited settings.
INTRODUCTION
Nipah virus (NiV) is a deadly zoonotic paramyxovirus with a broad host range. It first caused an outbreak of severe febrile encephalitis in Malaysia in 1998/1999 (1) . Since then, outbreaks occur almost annually in India and Bangladesh (2) (3) (4) . More recently, an outbreak was reported in the Philippines in 2014 (5) . The average case fatality rate from the NiV outbreaks thus far is 74.5z (4) . Bats are presumed to serve as a natural reservoir (6) (7) (8) , as is evidenced by detection of NiV in bats in South East Asia (9-11), China (12) , Madagascar (13) , and Ghana (14) . NiV's wide geographical range puts many populations at risk of infection with NiV. Transmission routes may include intermediate hosts such as pigs (1, 15) , or may occur directly from horse to human (5) , bat to human (2, 16) , or human to human, either from a live or deceased person (17, 18) . Current diagnostic procedures usually require the use of high containment facilities, which are not often accessible, especially in areas where NiV outbreaks have occurred. Commercial detection kits are still not widely available, perhaps due to the relatively low number of cases and limited localities. When available, the kits are too costly for use in continuous routine surveillance in resource-limited regions where NiV infection could be endemic. However, given the above mentioned factors, there is a continuous need for NiV surveillance programmes, especially among potentially susceptible populations, such as those living near forest fringes, and for early detection of unusual disease occurrences or potential outbreaks.
NiV encodes in its ～18.2 kb genome 6 proteins: the nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), glycoprotein (G), and large (L) (19) . The N protein is the most abundantly expressed protein in the virion and is a good immunogenic target for serological diagnosis. The membrane glycoproteins F and G, which are involved in virus attachment and fusion, are also good targets for antibody recognition and have been shown to induce neutralizing antibodies (20) . Routine serological diagnosis is performed using live or inactivated virus, which require the use of high containment facilities. The use of recombinantly produced NiV antigens for serological diagnosis via enzyme linked immunosorbent assay (ELISA) would provide a safer alternative.
This study aims to produce NiV N, F, and G proteins using an Escherichia coli expression system. Here we report the evaluation of these recombinant viral proteins in immunoblot assays using sera of NiV-infected patients from the 1998 outbreak in Malaysia and also from a patient with a case of late-onset relapsing NiV complication.
MATERIALS AND METHODS
Virus, serum samples, bacteria, and plasmid: Genomic RNA from the NiV strain NV/MY/99/VRI-2794 (GenBank ascension no. AJ564621) was used. This strain, isolated from pigs, shares high sequence similarity (＞99z) with human NiV isolates (15) . Sera from healthy donors were obtained from individuals with no known previous exposure to NiV. NiV-positive sera were obtained from archived serum samples from NiV encephalitis patients known to be positive for antiNiV IgM and IgG (data not shown). Serum was also Construction of recombinant plasmids: RNA was extracted from NiV using TRI Reagent  LS (Molecular Research Centre, Inc, Cincinnati, OH, USA) following the manufacturer's protocol and used as a template for cDNA synthesis using Superscript TM III reverse transcriptase (Invitrogen, Waltham, MA, USA). PCR amplification using Platinum TM Taq DNA polymerase high fidelity (Invitrogen Life Technologies, Waltham, MA, USA) and gene-specific primers were used to amplify the full length NiV nucleocapsid (N), and truncated NiV fusion (F) and attachment (G) proteins ( Table  1 ). The amplified DNA fragments were digested using the respective restriction enzymes outlined in Table 1 , and cloned into the vector pTriEx-3 Hygro. The recombinant plasmids, encompassing the respective NiV gene and a vector-derived histidine tag (his-tag) at the C-terminus, were transformed into the E. coli cloning host NovaBlue, and the positive transformants were verified by DNA sequencing. The plasmids were then transformed into the E. coli expression host RosettaBlue (DE3) pLacI.
Expression of recombinant NiV proteins: Transformed E. coli were cultured in Luria-Bertani (LB) broth containing ampicillin (50 mg/mL), chloramphenicol (34 mg/mL), tetracycline (12.5 mg/mL), and 1z glucose, until OD 600 ＞ 0.6. Expression was induced by the addition of isopropyl b-D thiogalactosidase (IPTG) to a final concentration of 1 mM. After 4 hours, the bacterial pellet was harvested by centrifugation at 10,000 × g for 10 min. The pellet was resuspended in lysis buffer (300 mM NaCl, 20 mM NaH 2 PO 4 , 2 mg/mL lysozyme, pH 7.4), incubated on ice for 30 min, and then sonicated using a Branson (Danbury, CT, USA) Sonifier 250. The cell lysate was centrifuged at 10,000 × g for 10 min at 49 C. The clarified supernatant containing the soluble protein fraction was harvested for purification. The pellet (inclusion body) was washed with PBS and used for purification of insoluble protein. Sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE) and immunoblot analyses were performed to confirm the expression of the target recombinant proteins, designated rNiV-N, rNiV-F and rNiV-G.
Purification of recombinant NiV proteins:
The histagged fused recombinant NiV proteins were purified by affinity chromatography using the HisTrap HP column attached to the AKTA TM Purifier System (GE Healthcare, South East, England). For purification under native conditions, the clarified supernatant containing the soluble rNiV-N was loaded onto the column, which had been equilibrated with binding buffer (1 M NaCl, 20 mM NaH 2 PO 4 , 20 mM imidazole, pH 7.4). The column was then washed to remove unspecific proteins and the bound protein was eluted with elution buffer (1 M NaCl, 20 mM NaH 2 PO 4 , 500 mM imidazole, pH 7.4). The eluted fractions were collected, and analysed by SDS-PAGE and immunoblotting.
The inclusion bodies containing insoluble rNiV-F and rNiV-G were solubilised in 6 M and 8 M urea, respectively. The solubilised protein was applied to a HisTrap HP column, and purification was performed under native conditions with minor exceptions. The binding buffer (500 mM NaCl, 20 mM NaH 2 PO 4 , 20 mM imidazole, pH 7.4) and elution buffer (500 mM NaCl, 20 mM NaH 2 PO 4 , 500 mM imidazole, pH 7.4) contained 6 M urea for rNiV-F, and 8 M urea for rNiV-G to maintain denaturing conditions. The eluted fractions were collected, and analysed as mentioned above.
Peptide mass fingerprinting and mass spectrometry: The purified proteins were separated by SDS-PAGE and stained with colloidal Coomassie blue (Bio-Rad, Hercules, CA, USA). Protein spots were excised from the protein bands according to the expected molecular masses of the expressed recombinant proteins. In the SDS-PAGE of purified rNiV-G and rNiV-F, there were additional proteins bands of lower molecular weight (MW) than predicted. These bands were also excised for identification. The gel plugs were destained, dried, and trypsin-digested (Sequencing Grade Modified Trypsin, Promega, Madison, WI, USA) for 2 hours at 379 C. The peptides were extracted from the gel plugs using solvent solution (0.1z trifluoroacetic acid and 50z acetonitrile) and transferred into new wells. The solvent was evaporated off, and the dried peptides were reconstituted with saturated matrix (a-cyano-4-hydroxycinnamic acid in 0.5z trifluoroacetic acid and 50z acetonitrile) and spotted onto sample slides. The sample slides were analysed using a 4800 Plus MALDI TOF/TOF Analyzer (Applied Biosystems/SCIEX, Foster City, CA, USA). The proteins were then identified by a peptide mass fingerprinting search of the NCBInr database using the MASCOT web engine (http://www.matrixscience.com/search _ form _ select. 
html).
Immunoblot analyses: Protein samples were mixed with loading buffer, boiled for 5 min and subjected to SDS-PAGE on denaturing 12.5z polyacrylamide gels. The separated proteins were then transferred to a nitrocellulose membrane and blocked with 3z bovine serum albumin (Sigma-Aldrich, St. Louis, MO, USA). For detection of the his-tagged recombinant proteins, the membrane was incubated with HisDetector Nickel AP-conjugate (KPL, Gaithersburg, MD, USA) at a 1:5,000 dilution for 1 hour at room temperature, and subsequently developed using the substrate BCIP/NBT (KPL). For immunoblot analysis using human sera, the membrane was incubated with serum samples at a 1:100 dilution for 1 hour at room temperature. Sera from 12 healthy individuals, 19 patients previously confirmed with acute NiV infection, and 1 patient with a relapsing NiV complication were included in the analyses. After washing with TBS-T (50 mM Tris-HCl, 150 mM NaCl, 0.05z Tween-20, pH 7.4), anti-human IgG monoclonal antibody conjugated to alkaline phosphatase (Sigma-Aldrich) at a 1:5,000 dilution was added to the membrane, and incubated for 1 hour at room temperature. The membrane was then washed and developed using the substrate BCIP/NBT as previously described (22) . Densitogram analysis of the immunoblot was performed using the image analysis software ImageJ (National Institutes of Health, Bethesda, MD, USA). To check for specificity, the recombinant proteins were also reacted with sera (1:100 dilution) from individuals confirmed to be previously infected with other related paramyxoviruses (mumps and measles), as well as other common infections, such as influenza A and dengue.
RESULTS

Expression and purification of the recombinant NiV proteins:
The rNiV-N protein was recovered in its soluble form both from the bacterial cytoplasm, and as protein aggregates inside inclusion bodies (Fig. 1A) , while rNiV-F and rNiV-G were expressed mainly in inclusion bodies ( Fig. 1B and C) . The recombinant his-tagged proteins were successfully purified from the cell lysate or inclusion bodies by means of affinity purification. After purification, immunoblot analysis revealed a protein band corresponding to the predicted molecular mass of ～66 kDa for rNiV-N, ～39 kDa for rNiV-F, and ～58 kDa for rNiV-G (Fig. 1) . However, in the purified products, an additional band for rNiV-F and multiple bands for rNiV-G of lower molecular mass were also observed. The identities of all observed bands were confirmed by mass spectrometry ( Table 2 ). The majority of the bands were removed after purification for rNiV-F protein, but not for rNiV-G protein. The yield of the purified protein was 4 mg/L for rNiV-N, 16 mg/L for rNiV-F, and 4 mg/L for rNiV-G.
Antigenicity of the recombinant NiV proteins: Sera from all 19 NiV-positive patients reacted with rNiV-N and rNiV-G proteins, while reactions involving the rNiV-F protein resulted in only faint bands (Fig. 2) . However, the serum from the patient with the relapsing NiV encephalitis complication did not react as robustly to the rNiV proteins as compared to the other positive patients' sera. This was especially notable for reactions with rNiV-N. The serum from the relapsing complication case reacted more with rNiV-G compared to rNiV-N and rNiV-F (Fig. 3) . None of the 12 healthy donors' sera produced a signal in reaction to either of the 3 recombinant NiV proteins. There was also no signal when reacted with sera from individuals positive for measles, mumps, influenza A, or dengue viruses (data not shown).
DISCUSSION
This study aimed to produce recombinant NiV proteins, namely the N, F, and G proteins, for potential use in serological surveillance for NiV infection. After purification, rNiV-N with high purity was obtained and observed as a single band in SDS-PAGE analysis, while additional band(s) were observed for purified rNiV-F and rNiV-G. These consistently observed lower MW bands were likely truncated forms of the recombinant proteins that could have resulted from the presence of internal translation initiation or ribosome binding sites. It is also possible that these bands resulted from Nterminal degradation during the protein translation and/or purification processes. The presence of the Cterminus his-tag indicate that the lower MW bands observed in the immunoblot were not the result of premature termination during translation. However, this observation was not reported by Eshaghi et al. (23) who produced the G protein in baculovirus. The purification step greatly reduced the abundance of the lower MW fragments the final product for rNiV-F, but not for rNiV-G. Further modification steps will likely help to improve the purity of rNiV-G. Nonetheless, we have shown that the lower MW fragments of the rNiV-F and rNiV-G proteins did not affect the discrimination of negative and positive sera in the downstream assays.
Of the 3 recombinant viral proteins, rNiV-N and rNiV-G proteins were found to be highly immunogenic as observed in the immunoblot assays. All the NiVpositive patients' sera reacted with the recombinant 
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NiV proteins, although to a lesser extent for rNiV-F. Interestingly, 4 of the positive sera reacted with the lower MW bands of rNiV-G (～25 kDa or ～30 kDa band), suggesting that these bands are also immunogenic. From mass spectrometric analysis of the 2 lower MW bands, the peptide sequences matched regions that correspond to the top of the globular head of the G protein. These regions are known to be involved in receptor binding (24) and are found to be immunogenic in many paramyxoviruses (25) . It is unclear, however, why the other patients' sera did not react with these bands. This may suggest that there is differential antibody response during infection in certain individuals. The weaker reaction between the rNiV-F protein and positive sera suggest that rNiV-F is not as immunogenic as the rNiV-N and rNiV-G proteins. Perhaps, the anti-F antibody in the sera is directed against the biologically active (26) or glycosylated forms of the viral protein. The recombinant NiV proteins were also probed with serum from a case of relapsing NiV encephalitis complication (21) . In contrast to all the other NiV positive patients' sera, this serum reacted mainly to the rNiV-G protein, followed by the rNiV-F and the rNiV-N proteins. The patient was known to be asymptomatic during the NiV outbreak in 1998/1999, during which the patient likely contracted the illness while being in contact with relatives who had NiV encephalitis. The patient was later diagnosed with an NiV infection primarily based on MRI imaging. In the report, serum from the patient was used to probe NiV-infected Vero cells. The patient was negative for anti-NiV IgM by immunofluorescence assay, indicating that it was not a primary infection at the time. However, the patient's serum tested positive for anti-NiV IgG, although the specific protein targeted by the IgG response could not be determined. It is possible that the patient is persistently infected with an NiV that has altered viral nucleocapsids, resulting in defective or non-infectious virus, as has been previously observed in other paramyxovirus infections, including mumps (27) and measles (28) . Thus, it is possible that the anti-N antibody produced against the mutated virus only weakly recognises rNiV-N in comparison to those in the acute positive patients' sera. It would be of great interest to further evaluate the NiV immunological profiles during relapse or late-onset NiV, which are not well characterized. Wong et al. (29) reported a rise in anti-NiV IgG titers in a case of a 4-month late-onset infection. However, the ELISA was performed using an infected cell lysate, rendering it impossible to determine if the increased titer was associated with a specific viral protein.
Recombinant proteins expressed in prokaryotic systems are not glycosylated. While specific N-glycosylation is required for biological function of the NiV gly-coproteins (30), we observed that it was not strictly required for immune recognition, particularly for rNiV-G. The present study demonstrates the ease and economic feasibility of producing and purifying recombinant NiV proteins expressed using an E. coli expression system. This process would enable production of recombinant NiV proteins in large quantities for use in serological assays. Our results suggest that the recombinant proteins, especially rNiV-N and rNiV-G, retain their immunogenicity and are recognized by anti-NiV antibodies in NiV patients' sera. Additionally, this study is the first to describe variation between the profiles of antigen-reactive bands identified via serodiagnostic immunoblots for a relapse patient's serum compared to those with acute infection. In line with the outcome of this study, the proteins can now be further evaluated and developed for use in resource limited settings for seroprevalence studies of NiV infection and for NiV biosurveillance of at risk populations, particularly in Malaysia. Lastly, our findings suggest further studies need to be performed on the case of relapsing NiV infection complication to have a better understanding about the immunopathology of the disease.
